06/12/2018 16:43:38

CLASS ACTION UPDATE for TRVN, HTHT and NKTR: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

NEW YORK, Dec. 06, 2018 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court and further details about the cases can be found at the links provided. There is no cost or obligation to you.

Trevena, Inc. (NASDAQGS: TRVN)

Class Period: May 2, 2016 - October 9, 2018

Lead Plaintiff Deadline: December 10, 2018

Join the action: https://www.zlk.com/pslra-1/trevena-inc-loss-form?wire=3

About the lawsuit: Throughout the class period, Trevena, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (a) during its meetings with the FDA prior to the start of the Class Period, Trevena had been advised that the FDA did not agree with certain aspects of the design of the Phase III clinical trial of Olinvo, including the proposed dosing, the proposed primary endpoint and the proposed non-inferiority margin for comparing morphine to Olinvo; (b) unless Trevena demonstrated that Olinvo was at least equally effective to morphine in treating post-operative pain in the Phase III clinical trial, the FDA would be unwilling to consider any secondary benefits Olinvo might confer in terms of reduced opioid-related adverse effects ("ORAEs"); (c) the FDA disagreed with how the safety data was being compiled in the Phase II clinical trial; (d) because the FDA did not agree with major tenants of the design of the Phase III clinical trial, it was highly unlikely that the FDA would find the data obtained from that clinical trial sufficient to support Trevena’s NDA; (e) because the Phase III clinical trial data being derived would not likely be deemed sufficient to support the NDA for Olinvo, the Company would not be able to market Olinvo as soon as it was leading the market to expect, if ever; and (f) as a result of the foregoing, the Company was not on track to achieve the commercial sales revenues from Olinvo as soon as Defendants had led the market to expect during the Class Period, if ever.

To learn more about the Trevena, Inc. class action contact jlevi@levikorsinsky.com.

Huazhu Group Limited (NASDAQ: HTHT)

Class Period: May 14, 2018 - August 28, 2018

Lead Plaintiff Deadline: December 7, 2018

Join the action: https://www.zlk.com/pslra-1/huazhu-group-limited-loss-form?wire=3

About the lawsuit: Huazhu Group Limited allegedly made materially false and/or misleading statements during the class period and/or failed to disclose that: (1) the Company lacked adequate security measures to protect customer information; (2) as a result of the foregoing, the Company would be susceptible to increased litigation risk and higher expenses; (3) as a result of the foregoing, the Company’s goodwill would potentially suffer, leading to lower revenues; and (4) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially false and/or misleading and/or lacked a reasonable basis.

To learn more about the Huazhu Group Limited class action contact jlevi@levikorsinsky.com.

Nektar Therapeutics (NASDAQ: NKTR)

Class Period: November 11, 2017 - October 2, 2018

Lead Plaintiff Deadline: December 31, 2018

Join the action: https://www.zlk.com/pslra-1/nektar-therapeutics-loss-form?wire=3

About the lawsuit: Nektar Therapeutics allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) prior studies which attempted to pegylate IL-2 failed; (2) the extended half-life of the Company's lead I-O candidate, NKTR-214, was unlikely to result in efficacy and created additional high-dosing safety concerns; (3) NKTR-214 was less effective than IL-2 alone; (4) the combination of NKTR-214 with nivolumab has yet to demonstrate significant positive results; and (5) as a result, Nektar’s public statements as set forth above were materially false and misleading at all relevant times.

To learn more about the Nektar Therapeutics class action contact jlevi@levikorsinsky.com.

You have until the lead plaintiff deadlines to request the court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP

Joseph E. Levi, Esq.

55 Broadway, 10th Floor

New York, NY 10006

jlevi@levikorsinsky.com

Tel: (212) 363-7500

Toll Free: (877) 363-5972

Fax: (212) 363-7171

www.zlk.com

250x148_zlk.jpg

Related content
18 Apr - 
Huazhu Group Limited Announces Its Preliminary Results ..
12 Apr - 
AMAG Pharmaceuticals Appoints New Members to Board of D..
05 Apr - 
Report: Developing Opportunities within 22nd Century Gr..
Del

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
Ingen indlæg

Regulatory news

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
HQDA Acquires 51% of Palua Airline and Tourism Companies
2
Upper Street Marketing Inc. Announces Strategic Partnership in Canada
3
Bragar Eagel & Squire, P.C. is Investigating Lyft, Inc. (LYFT) on Behalf of Stockholders and Encourages LYFT Investors to Contact the Firm
4
American Indian College Fund Celebrates 30 Years of Service to Native Americans Pursuing Higher Education
5
Oak Valley Bancorp Reports 1st Quarter Results

Related stock quotes

Nektar Therapeutics 31.68 1.6% Stock price increasing
China Lodging Group, Lim.. 42.43 1.5% Stock price increasing
Trevena Inc 1.500 0.0% Stock price unchanged

Latest news


Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
19 April 2019 10:08:28
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20190410.2 - EUROWEB5 - 2019-04-19 11:08:28 - 2019-04-19 10:08:28 - 1000 - Website: OKAY